You're using an outdated browser. Please upgrade to a modern browser for the best experience.
Respiratory Syncytial Virus Passive Immunoprophylaxis: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Camila Xu and Version 1 by Carlotta Biagi.

Respiratory syncytial virus (RSV) is a non-segmented, single-stranded, negative-sense RNA virus belonging to the Pneumoviridae family. It represents the leading cause of acute respiratory tract infections in children worldwide. Treatment of RSV infections is primarily supportive, including hydration and oxygen supplementation. To date, no vaccines are available and the only licensed passive immunoprophylaxis is palivizumab. Given is high cost, palivizumab is recomended only in high-risk infants, including those born preterm and those with hemodynamically significant congenital heart disease (CHD) and bronchopulmonary dysplasia (BPD). Nevertheless, many hospitalized RSV-infected children do not fully meet the criteria for immune prophylaxis. Thus, over the last decades efforts continued to develop new monoclonal antibodies with a potential better cost-effectiveness ratio compared to palivizumab.

Respiratory syncytial virus (RSV) is a non-segmented, single-stranded, negative-sense RNA virus belonging to the Pneumoviridae family. It represents the leading cause of acute respiratory tract infections in children worldwide. Treatment of RSV infections is primarily supportive, including hydration and oxygen supplementation.

  • respiratory syncytial virus
  • monoclonal antibodies
  • palivizumab
  • children
Please wait, diff process is still running!

References

  1. Collins, P.L.; Fearns, R.; Graham, B.S. Respiratory Syncytial Virus: Virology, Reverse Genetics, and Pathogenesis of Disease. Curr. Top. Microbiol. Immunol. 2013, 372, 3–38.
  2. Vandini, S.; Biagi, C.; Lanari, M. Respiratory Syncytial Virus: The Influence of Serotype and Genotype Variability on Clinical Course of Infection. Int. J. Mol. Sci. 2017, 18, 1717.
  3. Melero, J.A.; Mas, V.; McLellan, J.S. Structural, Antigenic and Immunogenic Features of Respiratory Syncytial Virus Glycoproteins Relevant for Vaccine Development. Vaccine 2017, 35, 461–468.
  4. Johnson, J.E.; Gonzales, R.A.; Olson, S.J.; Wright, P.F.; Graham, B.S. The Histopathology of Fatal Untreated Human Respiratory Syncytial Virus Infection. Mod. Pathol. Off. J. U. S. Can. Acad. Pathol. Inc. 2007, 20, 108–119.
  5. Simoes, E.A. Respiratory Syncytial Virus Infection. Lancet Lond. Engl. 1999, 354, 847–852.
  6. Shi, T.; McAllister, D.A.; O’Brien, K.L.; Simoes, E.A.F.; Madhi, S.A.; Gessner, B.D.; Polack, F.P.; Balsells, E.; Acacio, S.; Aguayo, C.; et al. Global, Regional, and National Disease Burden Estimates of Acute Lower Respiratory Infections Due to Respiratory Syncytial Virus in Young Children in 2015: A Systematic Review and Modelling Study. Lancet Lond. Engl. 2017, 390, 946–958.
  7. Stein, R.T.; Bont, L.J.; Zar, H.; Polack, F.P.; Park, C.; Claxton, A.; Borok, G.; Butylkova, Y.; Wegzyn, C. Respiratory Syncytial Virus Hospitalization and Mortality: Systematic Review and Meta-Analysis. Pediatr. Pulmonol. 2017, 52, 556–569.
  8. Ralston, S.L.; Lieberthal, A.S.; Meissner, H.C.; Alverson, B.K.; Baley, J.E.; Gadomski, A.M.; Johnson, D.W.; Light, M.J.; Maraqa, N.F.; Mendonca, E.A.; et al. Clinical Practice Guideline: The Diagnosis, Management, and Prevention of Bronchiolitis. Pediatrics 2014, 134, e1474–e1502.
  9. Caffrey Osvald, E.; Clarke, J.R. NICE Clinical Guideline: Bronchiolitis in Children. Arch. Dis. Child. Educ. Pract. Ed. 2016, 101, 46–48.
  10. Blanken, M.O.; Rovers, M.M.; Molenaar, J.M.; Winkler-Seinstra, P.L.; Meijer, A.; Kimpen, J.L.L.; Bont, L. Respiratory Syncytial Virus and Recurrent Wheeze in Healthy Preterm Infants. N. Engl. J. Med. 2013, 368, 1791–1799.
  11. Meissner, H.C. Viral Bronchiolitis in Children. N. Engl. J. Med. 2016, 374, 62–72.
  12. Meates-Dennis, M. Bronchiolitis. Arch. Dis. Child. Educ. Pract. 2005, 90, ep81–ep86.
  13. American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated Guidance for Palivizumab Prophylaxis among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection. Pediatrics 2014, 134, 415–420.
  14. Pignotti, M.S.; Carmela Leo, M.; Pugi, A.; De Masi, S.; Biermann, K.P.; Galli, L.; Vitali Rosati, G.; Buonocore, G.; Mugelli, A.; Dani, C.; et al. Consensus Conference on the Appropriateness of Palivizumab Prophylaxis in Respiratory Syncytial Virus Disease. Pediatr. Pulmonol. 2016, 51, 1088–1096.
  15. Mejias, A.; Ramilo, O. New Options in the Treatment of Respiratory Syncytial Virus Disease. J. Infect. 2015, 71 (Suppl. S1), S80–S87.
  16. Ventre, K.; Randolph, A.G. Ribavirin for Respiratory Syncytial Virus Infection of the Lower Respiratory Tract in Infants and Young Children. Cochrane Database Syst. Rev. 2007, CD000181.
  17. Wise, J. Do Not Prescribe Antibiotics for Bronchiolitis in Children, Doctors Are Reminded. BMJ 2016, 353, i3541.
  18. Farley, R.; Spurling, G.K.P.; Eriksson, L.; Del Mar, C.B. Antibiotics for Bronchiolitis in Children under Two Years of Age. Cochrane Database Syst. Rev. 2014, CD005189.
  19. Kneyber, M.C.J.; Blussé van Oud-Alblas, H.; van Vliet, M.; Uiterwaal, C.S.P.M.; Kimpen, J.L.L.; van Vught, A.J. Concurrent Bacterial Infection and Prolonged Mechanical Ventilation in Infants with Respiratory Syncytial Virus Lower Respiratory Tract Disease. Intensiv. Care Med. 2005, 31, 680–685.
  20. Thorburn, K.; Harigopal, S.; Reddy, V.; Taylor, N.; van Saene, H.K.F. High Incidence of Pulmonary Bacterial Co-Infection in Children with Severe Respiratory Syncytial Virus (RSV) Bronchiolitis. Thorax 2006, 61, 611–615.
  21. Greenes, D.S.; Harper, M.B. Low Risk of Bacteremia in Febrile Children with Recognizable Viral Syndromes. Pediatr. Infect. Dis. J. 1999, 18, 258–261.
  22. Snyder, R.L.; King, L.M.; Hersh, A.L.; Fleming-Dutra, K.E. Unnecessary Antibiotic Prescribing in Pediatric Ambulatory Care Visits for Bronchitis and Bronchiolitis in the United States, 2006-2015. Infect. Control Hosp. Epidemiol. 2020, 1–4.
  23. Kourlaba, G.; Kourkouni, E.; Spyridis, N.; Gerber, J.S.; Kopsidas, J.; Mougkou, K.; Lourida, A.; Zaoutis, T.E. Antibiotic Prescribing and Expenditures in Outpatient Paediatrics in Greece, 2010–2013. J. Antimicrob. Chemother. 2015, 70, 2405–2408.
  24. McCullough, A.R.; Pollack, A.J.; Plejdrup Hansen, M.; Glasziou, P.P.; Looke, D.F.; Britt, H.C.; Del Mar, C.B. Antibiotics for Acute Respiratory Infections in General Practice: Comparison of Prescribing Rates with Guideline Recommendations. Med. J. Aust. 2017, 207, 65–69.
  25. Schuh, S.; Lalani, A.; Allen, U.; Manson, D.; Babyn, P.; Stephens, D.; MacPhee, S.; Mokanski, M.; Khaikin, S.; Dick, P. Evaluation of the Utility of Radiography in Acute Bronchiolitis. J. Pediatr. 2007, 150, 429–433.
  26. Ralston, S.L.; Garber, M.D.; Rice-Conboy, E.; Mussman, G.M.; Shadman, K.A.; Walley, S.C.; Nichols, E.; Value in Inpatient Pediatrics Network Quality Collaborative for Improving Hospital Compliance with AAP Bronchiolitis Guideline (BQIP). A Multicenter Collaborative to Reduce Unnecessary Care in Inpatient Bronchiolitis. Pediatrics 2016, 137.
  27. Biagi, C.; Pierantoni, L.; Baldazzi, M.; Greco, L.; Dormi, A.; Dondi, A.; Faldella, G.; Lanari, M. Lung Ultrasound for the Diagnosis of Pneumonia in Children with Acute Bronchiolitis. BMC Pulm. Med. 2018, 18, 191.
  28. Biagi, C.; Dondi, A.; Scarpini, S.; Rocca, A.; Vandini, S.; Poletti, G.; Lanari, M. Current State and Challenges in Developing Respiratory Syncytial Virus Vaccines. Vaccines 2020, 8, 672.
  29. The IMpact-RSV Study Group. Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization from Respiratory Syncytial Virus Infection in High-Risk Infants. Pediatrics 1998, 102 Pt 1, 531–537.
  30. Soto, J.A.; Gálvez, N.M.S.; Pacheco, G.A.; Bueno, S.M.; Kalergis, A.M. Antibody Development for Preventing the Human Respiratory Syncytial Virus Pathology. Mol. Med. Camb. Mass 2020, 26, 35.
  31. Groothuis, J.R.; Simoes, E.A.; Levin, M.J.; Hall, C.B.; Long, C.E.; Rodriguez, W.J.; Arrobio, J.; Meissner, H.C.; Fulton, D.R.; Welliver, R.C. Prophylactic Administration of Respiratory Syncytial Virus Immune Globulin to High-Risk Infants and Young Children. The Respiratory Syncytial Virus Immune Globulin Study Group. N. Engl. J. Med. 1993, 329, 1524–1530.
  32. The PREVENT Study Group. Reduction of Respiratory Syncytial Virus Hospitalization among Premature Infants and Infants with Bronchopulmonary Dysplasia Using Respiratory Syncytial Virus Immune Globulin Prophylaxis. Pediatrics 1997, 99, 93–99.
  33. Simoes, E.A.; Sondheimer, H.M.; Top, F.H.; Meissner, H.C.; Welliver, R.C.; Kramer, A.A.; Groothuis, J.R. Respiratory Syncytial Virus Immune Globulin for Prophylaxis against Respiratory Syncytial Virus Disease in Infants and Children with Congenital Heart Disease. The Cardiac Study Group. J. Pediatr. 1998, 133, 492–499.
  34. Johnson, S.; Oliver, C.; Prince, G.A.; Hemming, V.G.; Pfarr, D.S.; Wang, S.C.; Dormitzer, M.; O’Grady, J.; Koenig, S.; Tamura, J.K.; et al. Development of a Humanized Monoclonal Antibody (MEDI-493) with Potent in Vitro and in Vivo Activity against Respiratory Syncytial Virus. J. Infect. Dis. 1997, 176, 1215–1224.
  35. Respiratory Syncytial Virus Immune Globulin Intravenous: Indications for Use. American Academy of Pediatrics Committee on Infectious Diseases, Committee on Fetus and Newborn. Pediatrics 1997, 99, 645–650.
  36. Mejias, A.; Garcia-Maurino, C.; Rodriguez-Fernandez, R.; Peeples, M.E.; Ramilo, O. Development and Clinical Applications of Novel Antibodies for Prevention and Treatment of Respiratory Syncytial Virus Infection. Vaccine 2017, 35, 496–502.
  37. ADMA Biologics, Inc. RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV Illness; Clinical Trial Registration NCT00632463. Available online: (accessed on 15 February 2021).
  38. Falsey, A.R.; Koval, C.; DeVincenzo, J.P.; Walsh, E.E. Compassionate Use Experience with High-Titer Respiratory Syncytical Virus (RSV) Immunoglobulin in RSV-Infected Immunocompromised Persons. Transpl. Infect. Dis. Off. J. Transplant. Soc. 2017, 19.
  39. ADMA Biologics, Inc. An Open Label, Multicenter, Study to Evaluate the Pharmacokinetics, Efficacy and Safety of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD); Clinical Trial Registration NCT01814800. Available online: (accessed on 20 February 2021).
  40. Weltzin, R.; Hsu, S.A.; Mittler, E.S.; Georgakopoulos, K.; Monath, T.P. Intranasal Monoclonal Immunoglobulin A against Respiratory Syncytial Virus Protects against Upper and Lower Respiratory Tract Infections in Mice. Antimicrob. Agents Chemother. 1994, 38, 2785–2791.
  41. Weltzin, R.; Traina-Dorge, V.; Soike, K.; Zhang, J.Y.; Mack, P.; Soman, G.; Drabik, G.; Monath, T.P. Intranasal Monoclonal IgA Antibody to Respiratory Syncytial Virus Protects Rhesus Monkeys against Upper and Lower Respiratory Tract Infection. J. Infect. Dis. 1996, 174, 256–261.
  42. Delagrave, S.; Catalan, J.; Sweet, C.; Drabik, G.; Henry, A.; Rees, A.; Monath, T.P.; Guirakhoo, F. Effects of Humanization by Variable Domain Resurfacing on the Antiviral Activity of a Single-Chain Antibody against Respiratory Syncytial Virus. Protein Eng. 1999, 12, 357–362.
  43. Wyde, P.R.; Moore, D.K.; Hepburn, T.; Silverman, C.L.; Porter, T.G.; Gross, M.; Taylor, G.; Demuth, S.G.; Dillon, S.B. Evaluation of the Protective Efficacy of Reshaped Human Monoclonal Antibody RSHZ19 against Respiratory Syncytial Virus in Cotton Rats. Pediatr. Res. 1995, 38, 543–550.
  44. Everitt, D.E.; Davis, C.B.; Thompson, K.; DiCicco, R.; Ilson, B.; Demuth, S.G.; Herzyk, D.J.; Jorkasky, D.K. The Pharmacokinetics, Antigenicity, and Fusion-Inhibition Activity of RSHZ19, a Humanized Monoclonal Antibody to Respiratory Syncytial Virus, in Healthy Volunteers. J. Infect. Dis. 1996, 174, 463–469.
  45. Johnson, S.; Griego, S.D.; Pfarr, D.S.; Doyle, M.L.; Woods, R.; Carlin, D.; Prince, G.A.; Koenig, S.; Young, J.F.; Dillon, S.B. A Direct Comparison of the Activities of Two Humanized Respiratory Syncytial Virus Monoclonal Antibodies: MEDI-493 and RSHZl9. J. Infect. Dis. 1999, 180, 35–40.
  46. Meissner, H.C.; Groothuis, J.R.; Rodriguez, W.J.; Welliver, R.C.; Hogg, G.; Gray, P.H.; Loh, R.; Simoes, E.A.F.; Sly, P.; Miller, A.K.; et al. Safety and Pharmacokinetics of an Intramuscular Monoclonal Antibody (SB 209763) against Respiratory Syncytial Virus (RSV) in Infants and Young Children at Risk for Severe RSV Disease. Antimicrob. Agents Chemother. 1999, 43, 1183–1188.
  47. FDA. “SYNAGIS® (PALIVIZUMAB) for Intramuscular Administration”. Available online: (accessed on 15 February 2021).
  48. Simoes, E.a.F.; Groothuis, J.R. Respiratory Syncytial Virus Prophylaxis—The Story so Far. Respir. Med. 2002, 96 (Suppl. B), S15–S24.
  49. Feltes, T.F.; Cabalka, A.K.; Meissner, H.C.; Piazza, F.M.; Carlin, D.A.; Top, F.H.; Connor, E.M.; Sondheimer, H.M.; Cardiac Synagis Study Group. Palivizumab Prophylaxis Reduces Hospitalization Due to Respiratory Syncytial Virus in Young Children with Hemodynamically Significant Congenital Heart Disease. J. Pediatr. 2003, 143, 532–540.
  50. Sáez-Llorens, X.; Castaño, E.; Null, D.; Steichen, J.; Sánchez, P.J.; Ramilo, O.; Top, F.H.; Connor, E. Safety and Pharmacokinetics of an Intramuscular Humanized Monoclonal Antibody to Respiratory Syncytial Virus in Premature Infants and Infants with Bronchopulmonary Dysplasia. The MEDI-493 Study Group. Pediatr. Infect. Dis. J. 1998, 17, 787–791.
  51. Subramanian, K.N.; Weisman, L.E.; Rhodes, T.; Ariagno, R.; Sánchez, P.J.; Steichen, J.; Givner, L.B.; Jennings, T.L.; Top, F.H.; Carlin, D.; et al. Safety, Tolerance and Pharmacokinetics of a Humanized Monoclonal Antibody to Respiratory Syncytial Virus in Premature Infants and Infants with Bronchopulmonary Dysplasia. MEDI-493 Study Group. Pediatr. Infect. Dis. J. 1998, 17, 110–115.
  52. Prevention of Respiratory Syncytial Virus Infections: Indications for the Use of Palivizumab and Update on the Use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn. Pediatrics 1998, 102, 1211–1216.
  53. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised Indications for the Use of Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous for the Prevention of Respiratory Syncytial Virus Infections. Pediatrics 2003, 112 Pt 1, 1442–1446.
  54. Diseases, C.I. Modified Recommendations for Use of Palivizumab for Prevention of Respiratory Syncytial Virus Infections. Pediatrics 2009, 124, 1694–1701.
  55. Hall, C.B.; Weinberg, G.A.; Blumkin, A.K.; Edwards, K.M.; Staat, M.A.; Schultz, A.F.; Poehling, K.A.; Szilagyi, P.G.; Griffin, M.R.; Williams, J.V.; et al. Respiratory Syncytial Virus-Associated Hospitalizations among Children Less than 24 Months of Age. Pediatrics 2013, 132, e341–e348.
  56. Stevens, T.P.; Sinkin, R.A.; Hall, C.B.; Maniscalco, W.M.; McConnochie, K.M. Respiratory Syncytial Virus and Premature Infants Born at 32 Weeks’ Gestation or Earlier: Hospitalization and Economic Implications of Prophylaxis. Arch. Pediatr. Adolesc. Med. 2000, 154, 55–61.
  57. Boyce, T.G.; Mellen, B.G.; Mitchel, E.F.; Wright, P.F.; Griffin, M.R. Rates of Hospitalization for Respiratory Syncytial Virus Infection among Children in Medicaid. J. Pediatr. 2000, 137, 865–870.
  58. Munoz, F.M.; Ralston, S.L.; Meissner, H.C. RSV Recommendations Unchanged after Review of New Data. AAP News 2021, 38, 1–4.
  59. Andabaka, T.; Nickerson, J.W.; Rojas-Reyes, M.X.; Rueda, J.D.; Bacic Vrca, V.; Barsic, B. Monoclonal Antibody for Reducing the Risk of Respiratory Syncytial Virus Infection in Children. Cochrane Database Syst. Rev. 2013.
  60. Wang, D.; Bayliss, S.; Meads, C. Palivizumab for Immunoprophylaxis of Respiratory Syncytial Virus (RSV) Bronchiolitis in High-Risk Infants and Young Children: A Systematic Review and Additional Economic Modelling of Subgroup Analyses. Health Technol. Assess. Winch. Engl. 2011, 15, 1–124.
  61. Luna, M.S.; Manzoni, P.; Paes, B.; Baraldi, E.; Cossey, V.; Kugelman, A.; Chawla, R.; Dotta, A.; Rodríguez Fernández, R.; Resch, B.; et al. Expert Consensus on Palivizumab Use for Respiratory Syncytial Virus in Developed Countries. Paediatr. Respir. Rev. 2020, 33, 35–44.
  62. Carbonell-Estrany, X.; Pérez-Yarza, E.G.; García, L.S.; Guzmán Cabañas, J.M.; Bòria, E.V.; Atienza, B.B.; IRIS (Infección Respiratoria Infantil por Virus Respiratorio Sincitial) Study Group. Long-Term Burden and Respiratory Effects of Respiratory Syncytial Virus Hospitalization in Preterm Infants-The SPRING Study. PLoS ONE 2015, 10, e0125422.
  63. Scheltema, N.M.; Nibbelke, E.E.; Pouw, J.; Blanken, M.O.; Rovers, M.M.; Naaktgeboren, C.A.; Mazur, N.I.; Wildenbeest, J.G.; van der Ent, C.K.; Bont, L.J. Respiratory Syncytial Virus Prevention and Asthma in Healthy Preterm Infants: A Randomised Controlled Trial. Lancet Respir. Med. 2018, 6, 257–264.
  64. Marlow, R.; Finn, A.; Henderson, J. Assessing the Association between Bronchiolitis in Infancy and Recurrent Wheeze: A Whole English Birth Cohort Case-Control Study. Thorax 2019, 74, 503–505.
  65. Fauroux, B.; Simões, E.A.F.; Checchia, P.A.; Paes, B.; Figueras-Aloy, J.; Manzoni, P.; Bont, L.; Carbonell-Estrany, X. The Burden and Long-Term Respiratory Morbidity Associated with Respiratory Syncytial Virus Infection in Early Childhood. Infect. Dis. Ther. 2017, 6, 173–197.
  66. Shi, T.; Ooi, Y.; Zaw, E.M.; Utjesanovic, N.; Campbell, H.; Cunningham, S.; Bont, L.; Nair, H.; RESCEU Investigators. Association Between Respiratory Syncytial Virus-Associated Acute Lower Respiratory Infection in Early Life and Recurrent Wheeze and Asthma in Later Childhood. J. Infect. Dis. 2020, 222 (Suppl. S7), S628–S633.
  67. Olchanski, N.; Hansen, R.N.; Pope, E.; D’Cruz, B.; Fergie, J.; Goldstein, M.; Krilov, L.R.; McLaurin, K.K.; Nabrit-Stephens, B.; Oster, G.; et al. Palivizumab Prophylaxis for Respiratory Syncytial Virus: Examining the Evidence Around Value. Open Forum Infect. Dis. 2018, 5, ofy031.
  68. Narayan, O.; Bentley, A.; Mowbray, K.; Hermansson, M.; Pivonka, D.; Kemadjou, E.N.; Belsey, J. Updated Cost-Effectiveness Analysis of Palivizumab (Synagis) for the Prophylaxis of Respiratory Syncytial Virus in Infant Populations in the UK. J. Med. Econ. 2020, 1–13.
  69. Bollani, L.; Baraldi, E.; Chirico, G.; Dotta, A.; Lanari, M.; Del Vecchio, A.; Manzoni, P.; Boldrini, A.; Paolillo, P.; Di Fabio, S.; et al. Revised Recommendations Concerning Palivizumab Prophylaxis for Respiratory Syncytial Virus (RSV). Ital. J. Pediatr. 2015, 41, 97.
  70. Figueras Aloy, J.; Carbonell Estrany, X. Update of Recommendations on the Use of Palivizumab as Prophylaxis in RSV Infections. An. Pediatría Engl. Ed. 2015, 82, 199.e1–199.e2.
  71. Gazzetta Ufficiale. Available online: (accessed on 23 January 2021).
  72. Cutrera, R.; Wolfler, A.; Picone, S.; Rossi, G.A.; Gualberti, G.; Merolla, R.; Del Vecchio, A.; Villani, A.; Midulla, F.; Dotta, A. Impact of the 2014 American Academy of Pediatrics Recommendation and of the Resulting Limited Financial Coverage by the Italian Medicines Agency for Palivizumab Prophylaxis on the RSV-Associated Hospitalizations in Preterm Infants during the 2016-2017 Epidemic Season: A Systematic Review of Seven Italian Reports. Ital. J. Pediatr. 2019, 45, 139.
  73. Capizzi, A.; Silvestri, M.; Orsi, A.; Cutrera, R.; Rossi, G.A.; Sacco, O. The Impact of the Recent AAP Changes in Palivizumab Authorization on RSV-Induced Bronchiolitis Severity and Incidence. Ital. J. Pediatr. 2017, 43, 71.
  74. Silvestri, M.; Marando, F.; Costanzo, A.M.; di Luzio Paparatti, U.; Rossi, G.A. Respiratory Syncytial Virus-Associated Hospitalization in Premature Infants Who Did Not Receive Palivizumab Prophylaxis in Italy: A Retrospective Analysis from the Osservatorio Study. Ital. J. Pediatr. 2016, 42, 40.
  75. Gazzetta Ufficiale. Available online: (accessed on 23 January 2021).
  76. Krilov, L.R.; Anderson, E.J. Respiratory Syncytial Virus Hospitalizations in US Preterm Infants after the 2014 Change in Immunoprophylaxis Guidance by the American Academy of Pediatrics. J. Perinatol. 2020, 40, 1135–1144.
  77. Anderson, E.J.; DeVincenzo, J.P.; Simões, E.A.F.; Krilov, L.R.; Forbes, M.L.; Pannaraj, P.S.; Espinosa, C.M.; Welliver, R.C.; Wolkoff, L.I.; Yogev, R.; et al. SENTINEL1: Two-Season Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks’ Gestational Age Not Receiving Immunoprophylaxis. Am. J. Perinatol. 2020, 37, 421–429.
  78. Resch, B. Product Review on the Monoclonal Antibody Palivizumab for Prevention of Respiratory Syncytial Virus Infection. Hum. Vaccines Immunother. 2017, 13, 2138–2149.
  79. Blanken, M.O.; Paes, B.; Anderson, E.J.; Lanari, M.; Sheridan-Pereira, M.; Buchan, S.; Fullarton, J.R.; Grubb, E.; Notario, G.; Rodgers-Gray, B.S.; et al. Risk Scoring Tool to Predict Respiratory Syncytial Virus Hospitalisation in Premature Infants. Pediatr. Pulmonol. 2018, 53, 605–612.
  80. Cetinkaya, M.; Oral, T.K.; Karatekin, S.; Cebeci, B.; Babayigit, A.; Yesil, Y. Efficacy of Palivizumab Prophylaxis on the Frequency of RSV-Associated Lower Respiratory Tract Infections in Preterm Infants: Determination of the Ideal Target Population for Prophylaxis. Eur. J. Clin. Microbiol. Infect. Dis. 2017, 36, 1629–1634.
  81. Mauskopf, J.; Margulis, A.V.; Samuel, M.; Lohr, K.N. Respiratory Syncytial Virus Hospitalizations in Healthy Preterm Infants: Systematic Review. Pediatr. Infect. Dis. J. 2016, 35, e229–e238.
  82. Weltzin, R.; Monath, T.P. Intranasal Antibody Prophylaxis for Protection against Viral Disease. Clin. Microbiol. Rev. 1999, 12, 383–393.
  83. Carbonell-Estrany, X.; Simões, E.A.F.; Dagan, R.; Hall, C.B.; Harris, B.; Hultquist, M.; Connor, E.M.; Losonsky, G.A.; Motavizumab Study Group. Motavizumab for Prophylaxis of Respiratory Syncytial Virus in High-Risk Children: A Noninferiority Trial. Pediatrics 2010, 125, e35–e51.
  84. Robbie, G.J.; Criste, R.; Dall’acqua, W.F.; Jensen, K.; Patel, N.K.; Losonsky, G.A.; Griffin, M.P. A Novel Investigational Fc-Modified Humanized Monoclonal Antibody, Motavizumab-YTE, Has an Extended Half-Life in Healthy Adults. Antimicrob. Agents Chemother. 2013, 57, 6147–6153.
  85. Simões, E.A.F.; Forleo-Neto, E.; Geba, G.P.; Kamal, M.; Yang, F.; Cicirello, H.; Houghton, M.R.; Rideman, R.; Zhao, Q.; Benvin, S.L.; et al. Suptavumab for the Prevention of Medically Attended Respiratory Syncytial Virus Infection in Preterm Infants. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2020.
  86. Griffin, M.P.; Yuan, Y.; Takas, T.; Domachowske, J.B.; Madhi, S.A.; Manzoni, P.; Simões, E.A.F.; Esser, M.T.; Khan, A.A.; Dubovsky, F.; et al. Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants. N. Engl. J. Med. 2020, 383, 415–425.
  87. Madhi, S.A.; Simões, E.A.F. Single-Dose Nirsevimab Prevents RSV Infection. J. Pediatr. 2021, 228, 310–313.
  88. MedImmune LLC. A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-Life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY); Clinical Trial Registration NCT03979313. Available online: (accessed on 10 February 2021).
  89. MedImmune LLC. A Phase 2/3 Randomized, Double-Blind, Palivizumab-Controlled Study to Evaluate the Safety of MEDI8897, a Monoclonal Antibody With an Extended Half-Life Against Respiratory Syncytial Virus, in High-Risk Children (MEDLEY); Clinical trial registration NCT03959488. Available online: (accessed on 10 February 2021).
  90. AstraZeneca. A Phase 2, Open-Label, Uncontrolled, Single-Dose Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Occurrence of Antidrug Antibody for Nirsevimab in Immunocompromised Japanese Children ≤ 24 Months of Age; Clinical Trial Registration NCT04484935. Available online: (accessed on 10 February 2021).
  91. Merck Sharp & Dohme Corp. A Phase 2a Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Participants Inoculated With Experimental Respiratory Syncytial Virus; Clinical Trial Registration NCT04086472. Available online: (accessed on 10 February 2021).
  92. Merck Sharp & Dohme Corp. A Double-Blind, Randomized, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1654 in Pre-Term and Full-Term Infants; Clinical Trial Registration NCT03524118. Available online: (accessed on 10 February 2021).
  93. Abarca, K.; Jung, E.; Fernández, P.; Zhao, L.; Harris, B.; Connor, E.M.; Losonsky, G.A.; Motavizumab Study Group. Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Motavizumab, a Humanized, Enhanced-Potency Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus Infection in at-Risk Children. Pediatr. Infect. Dis. J. 2009, 28, 267–272.
  94. Fernández, P.; Trenholme, A.; Abarca, K.; Griffin, M.P.; Hultquist, M.; Harris, B.; Losonsky, G.A.; the Motavizumab Study Group. A Phase 2, Randomized, Double-Blind Safety and Pharmacokinetic Assessment of Respiratory Syncytial Virus (RSV) Prophylaxis with Motavizumab and Palivizumab Administered in the Same Season. BMC Pediatr. 2010, 10, 38.
  95. Feltes, T.F.; Sondheimer, H.M.; Tulloh, R.M.R.; Harris, B.S.; Jensen, K.M.; Losonsky, G.A.; Griffin, M.P.; Motavizumab Cardiac Study Group. A Randomized Controlled Trial of Motavizumab versus Palivizumab for the Prophylaxis of Serious Respiratory Syncytial Virus Disease in Children with Hemodynamically Significant Congenital Heart Disease. Pediatr. Res. 2011, 70, 186–191.
  96. Regeneron Pharmaceuticals. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants; Clinical Trial Registration NCT02325791. Available online: (accessed on 1 February 2021).
  97. Inc, R.P. Regeneron to Discontinue Development of Suptavumab for Respiratory Syncytial Virus. Available online: (accessed on 14 February 2021).
  98. Tang, A.; Chen, Z.; Cox, K.S.; Su, H.-P.; Callahan, C.; Fridman, A.; Zhang, L.; Patel, S.B.; Cejas, P.J.; Swoyer, R.; et al. A Potent Broadly Neutralizing Human RSV Antibody Targets Conserved Site IV of the Fusion Glycoprotein. Nat. Commun. 2019, 10, 4153.
  99. Aliprantis, A.O.; Wolford, D.; Caro, L.; Maas, B.M.; Ma, H.; Montgomery, D.L.; Sterling, L.M.; Hunt, A.; Cox, K.S.; Vora, K.A.; et al. A Phase 1 Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of a Respiratory Syncytial Virus Neutralizing Monoclonal Antibody MK-1654 in Healthy Adults. Clin. Pharmacol. Drug Dev. 2020.
  100. Zhu, Q.; McLellan, J.S.; Kallewaard, N.L.; Ulbrandt, N.D.; Palaszynski, S.; Zhang, J.; Moldt, B.; Khan, A.; Svabek, C.; McAuliffe, J.M.; et al. A Highly Potent Extended Half-Life Antibody as a Potential RSV Vaccine Surrogate for All Infants. Sci. Transl. Med. 2017, 9.
  101. Griffin, M.P.; Khan, A.A.; Esser, M.T.; Jensen, K.; Takas, T.; Kankam, M.K.; Villafana, T.; Dubovsky, F. Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults. Antimicrob. Agents Chemother. 2017, 61, e01714-16.
  102. Domachowske, J.B.; Khan, A.A.; Esser, M.T.; Jensen, K.; Takas, T.; Villafana, T.; Dubovsky, F.; Griffin, M.P. Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-Life Single-Dose Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants. Pediatr. Infect. Dis. J. 2018, 37, 886–892.
  103. Corti, D.; Bianchi, S.; Vanzetta, F.; Minola, A.; Perez, L.; Agatic, G.; Guarino, B.; Silacci, C.; Marcandalli, J.; Marsland, B.J.; et al. Cross-Neutralization of Four Paramyxoviruses by a Human Monoclonal Antibody. Nature 2013, 501, 439–443.
  104. Schuster, J.E.; Cox, R.G.; Hastings, A.K.; Boyd, K.L.; Wadia, J.; Chen, Z.; Burton, D.R.; Williamson, R.A.; Williams, J.V. A Broadly Neutralizing Human Monoclonal Antibody Exhibits in Vivo Efficacy against Both Human Metapneumovirus and Respiratory Syncytial Virus. J. Infect. Dis. 2015, 211, 216–225.
  105. Wen, X.; Mousa, J.J.; Bates, J.T.; Lamb, R.A.; Crowe, J.E.; Jardetzky, T.S. Structural Basis for Antibody Cross-Neutralization of Respiratory Syncytial Virus and Human Metapneumovirus. Nat. Microbiol. 2017, 2, 16272.
  106. Mousa, J.J.; Binshtein, E.; Human, S.; Fong, R.H.; Alvarado, G.; Doranz, B.J.; Moore, M.L.; Ohi, M.D.; Crowe, J.E. Human Antibody Recognition of Antigenic Site IV on Pneumovirus Fusion Proteins. PLoS Pathog. 2018, 14, e1006837.
  107. Boyoglu-Barnum, S.; Todd, S.O.; Chirkova, T.; Barnum, T.R.; Gaston, K.A.; Haynes, L.M.; Tripp, R.A.; Moore, M.L.; Anderson, L.J. An Anti-G Protein Monoclonal Antibody Treats RSV Disease More Effectively than an Anti-F Monoclonal Antibody in BALB/c Mice. Virology 2015, 483, 117–125.
  108. Caidi, H.; Miao, C.; Thornburg, N.J.; Tripp, R.A.; Anderson, L.J.; Haynes, L.M. Anti-Respiratory Syncytial Virus (RSV) G Monoclonal Antibodies Reduce Lung Inflammation and Viral Lung Titers When Delivered Therapeutically in a BALB/c Mouse Model. Antivir. Res. 2018, 154, 149–157.
  109. Tian, P.; Wang, Y.; Liu, H.; Yang, Y.; Wu, X.; Wei, H.; Chen, T. Preparation and Evaluation of the Fully Humanized Monoclonal Antibody GD-MAb Against Respiratory Syncytial Virus. Front. Cell. Infect. Microbiol. 2019, 9, 275.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
Academic Video Service
Feedback